<?xml version="1.0" encoding="UTF-8"?>
<ref id="B152-microorganisms-08-01017">
 <label>152.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Cabrera</surname>
    <given-names>S.M.</given-names>
   </name>
   <name>
    <surname>Wang</surname>
    <given-names>X.</given-names>
   </name>
   <name>
    <surname>Chen</surname>
    <given-names>Y.G.</given-names>
   </name>
   <name>
    <surname>Jia</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Kaldunski</surname>
    <given-names>M.L.</given-names>
   </name>
   <name>
    <surname>Greenbaum</surname>
    <given-names>C.J.</given-names>
   </name>
   <collab>Type 1 Diabetes Trialnet Canakinumab Study Group</collab>
   <name>
    <surname>Mandrup-Poulsen</surname>
    <given-names>T.</given-names>
   </name>
   <collab>AIDA Study Group</collab>
   <name>
    <surname>Hessner</surname>
    <given-names>M.J.</given-names>
   </name>
  </person-group>
  <article-title>Interleukin-1 antagonism moderates the inflammatory state associated with Type 1 diabetes during clinical trials conducted at disease onset</article-title>
  <source>Eur. J. Immunol.</source>
  <year>2016</year>
  <volume>46</volume>
  <fpage>1030</fpage>
  <lpage>1046</lpage>
  <pub-id pub-id-type="doi">10.1002/eji.201546005</pub-id>
  <?supplied-pmid 26692253?>
  <pub-id pub-id-type="pmid">26692253</pub-id>
 </element-citation>
</ref>
